title: Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.
authors.forename: Paul
authors.initials: P
authors.lastname: Hamberg
authors.forename: Floris A
authors.initials: FA
authors.lastname: De Jong
authors.forename: Dieta
authors.initials: D
authors.lastname: Brandsma
authors.forename: Jaap
authors.initials: J
authors.lastname: Verweij
authors.forename: Stefan
authors.initials: S
authors.lastname: Sleijfer
mesh_terms: D000328:Adult; D000932:Antiemetics / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D001259:Ataxia / Q000139:chemically induced; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives*; D000069287:Capecitabine; D002490:Central Nervous System / Q000187:drug effects*; D015179:Colorectal Neoplasms / Q000473:pathology / Q000556:secondary*; D003603:Cytotoxins / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003907:Dexamethasone / Q000627:therapeutic use; D004401:Dysarthria / Q000139:chemically induced*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D017829:Granisetron / Q000627:therapeutic use; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D018228:Sarcoma, Small Cell / Q000188:drug therapy* / Q000556:secondary; D012702:Serotonin Antagonists / Q000627:therapeutic use; D059004:Topoisomerase I Inhibitors
chemical_list: D000932:Antiemetics; D000972:Antineoplastic Agents, Phytogenic; D002166:Camptothecin; D000069287:Capecitabine; D003603:Cytotoxins; D003841:Deoxycytidine; D003907:Dexamethasone; D005472:Fluorouracil; D017829:Granisetron; D000077146:Irinotecan; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D012702:Serotonin Antagonists; D059004:Topoisomerase I Inhibitors